Presidential Symposium

(S100) AN INTACT GUT MICROBIOME PROTECTS GENETICALLY PREDISPOSED MICE AGAINST LEUKEMIA

Carolina Vicente-Dueñas, Stefan Janssen, Marina Oldenburg, et al.

The authors conclude: 

Our results demonstrate that the microbiome profile provides a biomarker that might be used to identify predisposed carriers at risk to develop leukemia. Furthermore, we identify microbiome deprivation via antibiotic treatment as a risk factor for leukemia development. We anticipate that by modulating the microbiome early in life the risk to develop leukemia may be reduced.

--------------------------------------------------------------------------------------------------------------------------------------------------------

(S101) POSITRON EMISSION TOMOGRAPHY GUIDED OMISSION OF RADIOTHERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE III HD17 TRIAL BY THE GHSG

Peter Borchmann

The authors conclude: 

PET4-negativity after treatment with “2+2” chemotherapy in patients with newly diagnosed early-stage unfavourable HL allows omission of consolidation RT without relevant loss of efficacy. PET-guided therapy thereby reduces the proportion of patients at risk for late effects from irradiation.

--------------------------------------------------------------------------------------------------------------------------------------------------------

(S102) TBI OR CHEMOTHERAPY BASED CONDITIONING FOR CHILDREN AND ADOLESCENTS WITH ALL: A PROSPECTIVE RANDOMIZED MULTICENTER-STUDY “FORUM” ON BEHALF OF THE AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG AND EBMT-PD-WP

Christina Peters, Jean-Hugues Dalle, Franco Locatelli, et al.

The authors conclude: 

Overall survival in patients ≥ 4 years of age following HSCT from a MSD or MUD with TBI/eto conditioning is superior as compared to chemo-conditioning regimen due to significantly lower relapse-incidence. Busulfan- or treosulfan-based chemo-conditioning regimen including fludarabine and thiotepa are valuable alternative options for patients who are ineligible for TBI either because of age or co-morbidity.  There was no significant difference in 2-yr TRM or incidence of acute and chronic GVHD. Prospective monitoring of late complications, endocrine functions and incidence of secondary malignancies will contribute to better define the advantages and limitations of the 3 conditioning approaches.

--------------------------------------------------------------------------------------------------------------------------------------------------------

(S103) NETRIN-1 REGULATES HEMATOPOIETIC STEM CELL DORMANCY AND FUNCTION VIA ITS RECEPTOR NEOGENIN WITH IMPLICATIONS FOR STEM CELL AGEING

Simon Renders, Nicolas Rama, Arthur Flohr Svendsen, et al.

The authors conclude: 

We identify the Ntn1- Neo1 ligand-receptor pair as a novel signaling axis linking periarteriolar cells to HSCs. This promotes HSC maintenance through dormancy, while disruption leads to cell cycle activation, loss of self-renewal and HSC exhaustion. The Ntn1-Neo1 axis weakens upon physiological ageing, inducing age dependent changes of HSC and may offer a molecular target for HSC rejuvenation.

--------------------------------------------------------------------------------------------------------------------------------------------------------

(S104) A NOVEL ROLE FOR IRON REGULATORY PROTEINS IN HEMATOPOIESIS

Michael Bonadonna, Elisabeth Tybl, Gael Palais, et al.

The authors conclude: 

IRPs seem not strictly required for the multiplication of stem and progenitor cells, but are critical at later stages of hematopoiesis, in particular for the development of neutrophils. This work uncovers a previously unrecognized role for the IRPs and iron metabolism in adult hematopoiesis, beyond the making of red blood cells.

--------------------------------------------------------------------------------------------------------------------------------------------------------

(LB2600) PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PEMBROLIZUMAB (PEMBRO) VERSUS BRENTUXIMAB VEDOTIN (BV) FOR TREATMENT OF RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL): KEYNOTE-204

P. L. Zinzani, R. Ramchandren, A. Santoro, et al.

The authors conclude: 

Pembro was superior to BV in pts with R/R cHL and demonstrated across all subgroups statistically significant and clinically meaningful improvement in PFS. Safety was consistent with previous reports. These results support pembro monotherapy as the new standard of care for pts with R/R/cHL.